Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability-Reference-Cited by-同舟云学术

Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability

Published:2016-03-15 Issue:4 Volume:39 Page:499-501
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Riddle Matthew C.¹

Affiliation:

1. Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR

Funder

Russell Standley and Rose Hastings Memorial Trusts

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/39/4/499/626195/dc152754.pdf

Reference20 articles.

1. PRNewswire. Lilly ends basal insulin peglispro development program, 4 December 2015. Available from http://www.prnewswire.com/news-releases/lilly-ends-basal-insulin-peglispro-development-program-300188076.html. Accessed 24 November 2015

2. PRNewswire. Lilly announces update on regulatory submission timing for basal insulin peglispro, 23 February 2015. Available from http://www.prnewswire.com/news-releases/lilly-announces-update-on-regulatory-submission-timing-for-basal-insulin-peglispro-30003944.html. Accessed 24 November 2015

3. PEGylated insulin lispro, (LY2605541)—a new basal insulin analogue;Caparrotta;Diabetes Obes Metab,2014

4. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus;Sinha;Diabetes Obes Metab,2014

5. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5;Buse;Diabetes Care,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Chemoenzymatic Strategy for Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals;2024-08-13

2. Evolution of insulin therapy: past, present, future;Problems of Endocrinology;2024-01-24

3. Endpoints in NASH Clinical Trials: Are We Blind in One Eye?;Metabolites;2024-01-08

4. D-VITylation: Harnessing the biology of vitamin D to improve the pharmacokinetic properties of peptides and small proteins;International Journal of Pharmaceutics;2022-08

5. Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease;Process Biochemistry;2021-11